Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Rheumatology (2020) Vol. 32, Iss. 4, pp. 371-379
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Adam S. Cheifetz, María T. Abreu, Waqqas Afif, et al.
The American Journal of Gastroenterology (2021) Vol. 116, Iss. 10, pp. 2014-2025
Open Access | Times Cited: 151
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro–de Acosta, Irina Blumenstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 46
Precision medicine and drug optimization in adult inflammatory bowel disease patients
Sophie Vieujean, Édouard Louis
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 12
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis
Jeffrey A. Lowell, G.V.R.K. Sharma, Vincent Chua, et al.
Digestive Diseases and Sciences (2024)
Closed Access | Times Cited: 2
De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review
Javier P. Gisbert, María Chaparro
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 642-658
Closed Access | Times Cited: 6
Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
Marten Beeg, Cesare Burti, Eleonora Allocati, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 14
Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis
Noemí Manceñido, Blanca Novella Arribas, Gustavo Mora Navarro, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 3, pp. 421-428
Closed Access | Times Cited: 5
Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey
Lisa Schots, Lynda Grine, Rani Soenen, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 3, pp. 1473-1481
Open Access | Times Cited: 13
The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
Fotios S. Fousekis
Annals of Gastroenterology (2021)
Open Access | Times Cited: 12
Preactive therapeutic drug monitoring (TDM): time to redefine TDM
Konstantinos Papamichael, Nurulamin M Noor, Adam S. Cheifetz
Scandinavian Journal of Gastroenterology (2024) Vol. 59, Iss. 8, pp. 1021-1022
Closed Access | Times Cited: 1
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases
W Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 10, pp. 3776-3789
Open Access | Times Cited: 10
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis
Rani Soenen, Zhigang Wang, Lynda Grine, et al.
Clinical and Experimental Dermatology (2022) Vol. 47, Iss. 7, pp. 1324-1336
Open Access | Times Cited: 6
PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice
Abigail Ferreira, Helena Martins, José Carlos Oliveira, et al.
Life (2021) Vol. 11, Iss. 11, pp. 1130-1130
Open Access | Times Cited: 8
PBPK Modeling and Simulation and Therapeutic Drug Monitoring: Possible Ways for Antibiotic Dose Adjustment
Abigail Ferreira, Rui A. S. Lapa, Nuno Vale
Processes (2021) Vol. 9, Iss. 11, pp. 2087-2087
Open Access | Times Cited: 8
Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial
Adam S. Cheifetz, Niels Vande Casteele, Zhongya Wang, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 3, pp. 485-490
Open Access | Times Cited: 5
Real-world impact of infliximab precision-guided dosing on management of patients with IBD
Bincy Abraham, David Ziring, Thierry Dervieux, et al.
The American Journal of Managed Care (2023) Vol. 29, Iss. Suppl 12, pp. S227-S235
Open Access | Times Cited: 2
Progress in the Study of Inflammatory Bowel Disease Patients with Primary Non-Responsiveness
Yixue Liu, Xiaoping Tan
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 01, pp. 72-85
Open Access
Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review)
Tsviatko Alexandrov, B. A. Vykova
Koloproktologia (2024) Vol. 23, Iss. 2, pp. 173-183
Open Access
Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
Konstantinos Papamichael, Adam S. Cheifetz
Alimentary Pharmacology & Therapeutics (2024)
Open Access
Relationships between Secukinumab Concentrations, Disease Activity, and Il-17a Levels in Psoriasis: A Cross-Sectional Observational Study
K. Zhu, Lu Zhou, Lei Cao, et al.
(2024)
Closed Access
Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study
Axel Dignaß, Isabel Redondo, Petra Streit, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 12, pp. 1695-1705
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top